At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Study of ABT-888, An Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children With Newly Diagnosed Diffuse Pontine Gliomas (DIPG)
In Brief
A Phase 2 clinical trial evaluating 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, and 4 other interventions for Anaplastic Astrocytoma and 12 related conditions. Completed, enrolled 66 participants across 12 sites.
Detailed Summary
This phase I/II trial studies the side effects and the best dose of veliparib when given together with radiation therapy and temozolomide and to see how well they work in treating younger patients newly diagnosed with diffuse pontine gliomas. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells either by killing the cells or by stopping them from dividing. Giving veliparib with radiation therapy and temozolomide may kill more tumor cells.
Study Details
Timeline
Interventions
Undergo 3D-CRT
Undergo IMRT
Optional correlative studies
Correlative studies
Given PO
Given PO